Posted by Michael Wonder on 12 Sep 2023
MorphoSys receives US FDA fast track designation for tulmimetostat in endometrial cancer
12 September 2023 - Tulmimetostat follows pelabresib (2018) and tafasitamab (2014) as the company’s third clinical program to receive fast track designation.
MorphoSys today announced that the US FDA granted fast track designation for tulmimetostat, the company’s investigational next-generation dual inhibitor of EZH2 and EZH1, for the treatment of patients with advanced, recurrent or metastatic endometrial cancer harboring AT rich interacting domain containing protein 1A mutations and who have progressed on at least one prior line of treatment.
